Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 344 followers
Latest posts
Last updated about 1 hour ago
Cordis’ sirolimus drug-coated balloon earns FDA approval as a breakthrough device
about 1 hour ago
The FDA gave the green light to a first and only sirolimus...
Celldex monoclonal antibody rebounds with pair of phase 3 wins for chronic skin condition
about 2 hours ago
Celldex touted a double phase 3 trial win in patients with treatment-refractory...
Amgen’s Horizon-acquired fusion protein eases Sjögren's severity in ph. 3 win
about 2 hours ago
An investigational drug for the autoimmune condition Sjögren's disease has scored a...
Vertex’s midstage data amplify kidney disease market opportunity
about 3 hours ago
Vertex has reported positive phase 2b data for its kidney disease prospect...
Lexeo takes up the Mantle in $8M acquisition for Friedreich ataxia assets
about 3 hours ago
Lexeo Therapeutics has agreed to acquire Mantle Therapeutics via an upfront payment...
Otsuka heads to FDA as Ionis-partnered ALS drug hits primary phase 3 endpoint
about 3 hours ago
A phase 3 study of Otsuka and Ionis Pharmaceuticals’ amyotrophic lateral sclerosis...
Siemens Healthineers and Novo team up on fatty liver disease awareness, testing
about 3 hours ago
Siemens Healthineers is joining forces with Novo to help boost awareness and...
DPHARM: Where to begin with AI in clinical trials?
about 4 hours ago
The promise of AI to transform the clinical trial process is being...
Boehringer, Envisagenics sign $1B multi-target oncology collaboration
about 5 hours ago
Boehringer Ingelheim and AI drug discovery company Envisagenics have agreed to a...
Roche’s GLP-1/GIP drug hits in phase 2 diabetes trial, fueling best-in-disease hopes
about 8 hours ago
A phase 2 trial of Roche’s dual GLP-1/GIP receptor agonist has hit...
Iambic maintains momentum from string of Big Pharma partnerships by aiming for IPO
about 9 hours ago
Iambic Therapeutics is maintaining the momentum generated by its recent megaround and...
Novo struggles to appease restive investors with consumer plans, blockbuster ambitions
1 day ago
With reports leaking out of investor discontent, CEO Mike Doustdar opened Novo's...